{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-26-000030","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2026-07-27T23:29:38+00:00","discovered_at":"2026-07-28T10:05:00.380547+00:00","generated_at":"2026-07-28T10:05:44.872914+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nautilus Q2 net loss $14.5M; first revenue $0.2M; delays broadscale assay, accelerates proteoforms","bullets":["Revenue of $0.2M from MJFF grant and first Early Access customer; net loss $14.5M vs $15.0M YoY.","Operating expenses $15.9M, down 7% YoY; cash, equivalents and investments $129.2M.","Voyager platform pre-orders expected early 2027, shipments mid-2027; proteoform kits GA mid-2027.","Broadscale assay delayed; no 2027 GA timeline; company reallocating resources to proteoforms.","AKT1 proteoform assay Early Access late 2026; second oncology assay mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-26-000030","json":"https://secwatch.observer/filing/0001808805-26-000030.json","markdown":"https://secwatch.observer/filing/0001808805-26-000030.md","text":"https://secwatch.observer/filing/0001808805-26-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000030/0001808805-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000030/naut-20260728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-28T10:05:44.872914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}